… GSK-3 is an atypical kinase that is constitutively active and … to its inhibitory effect on two key
broad targets, namely, GSK-… receptor AMPA type subunit 1 (GluA1) receptor-mediated Ca 2…

… target of rapamycin (mTOR), mitogen-activated protein kinases (MAPK) or glycogen synthase
kinase 3 (GSK-3)… Likewise, ketamine has been reported to activate mTOR and downstream …

… Other AMPA-targeted agents in different stages of the drug … high-throughput screening
format by assaying CREB-mediated β-… Glycogen synthase kinase-3 (GSK-3) is a multifunctional …

… with the promotion of mammalian target of rapamycin (mTOR) and … neural flexibility in key
limbic regions, allowing for a … the mTOR pathway mediates ketamine’s antidepressant effects (…

… are directly involved in immunity regulation [73]. Lithium’s … mediate intracellular calcium levels,
which are regulated by SNP. … The protein and mRNA expression of GSK-3 β in the DLPFC …

… aim was to assess if subchronic administration of ketamine … to dismiss the possibility that the
performance in the FST or CPP … Antidepressant effects of AMPA and ketamine combination: …

… than 7Li in suppression of ketamine-induced hyperactivity in a … Research Goal: the overall
purpose of this research was to … for use with GSK-3β to allow for high-throughput screening of …

… NMDA receptor (NMDAR) antagonist esketamine (the S-isomer of … ketamine effects on
potential targets/pathways linked to MDD, including AMPA receptor, the mammalian target of …

… neurotransmission via regulation of synaptic AMPA receptors. … CRISPR/Cas9 mediated
genetic targeting for the interrogation of … GSK3 regulates AMPA, NMDA receptors and synaptic …

… and showed worsened cognitive performance upon exposure to … NMDA receptors, resulting
in synaptic plasticity loss and … Glycogen synthase kinase-3 (GSK-3) is triggered by ROS, …